A mimic of phosphorylated prolactin induces apoptosis by activating AP-1 and upregulating p21/waf1 in human prostate cancer PC3 cells

LIANLIAN DU¹ and WEI WU¹,²

¹Department of Epidemiology and Health Statistics, School of Public Health and Family Medicine;
²Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, P.R. China

Received March 28, 2012; Accepted July 9, 2012

DOI: 10.3892/ol.2012.876

Abstract. A mimic of phosphorylated prolactin (S179D PRL) has been demonstrated to inhibit prostate cancer cell growth in vitro and in vivo; however, the mechanisms involved in this process remain unknown. In this study, we identified that a four-day treatment of S179D PRL (1 µg/ml) in human prostate PC3 cancer cells activated JNK, c-fos and c-jun, and led to apoptosis. We also demonstrated that p21/waf1 was upregulated in cells transfected with the human PRL receptor (Sib) following a four-day incubation with S179D PRL (1 µg/ml). Once the cells were cotransfected with Sib and either c-fos, c-jun or the c-fos/c-jun constructs for 24 h, S179D PRL activated JNK, c-fos and c-jun, and induced apoptosis in the c-fos/c-jun transfected cells. Additionally, S179D PRL upregulated p21 luciferase activity in the cells transfected with the Sib, activating protein-1 (AP-1) (7x) Luc or p21 Luc constructs. SP600125 (25 µM), a JNK blocker, inhibited the upregulation of AP-1 Luc and p21 Luc in the c-fos/c-jun transfected cells.

These results demonstrate that S179D PRL activates JNK and AP-1, which leads to p21 upregulation and apoptosis in human prostate PC3 cancer cells.

Introduction

Overexpression of unmodified prolactin (U-PRL) promotes prostate and breast cancer; however, phosphorylated PRL has the opposite effect (1). A recombinant PRL was constructed and used as a mimic of the phosphorylated PRL (S179D PRL). In a previous study, we demonstrated that S179D PRL inhibited breast and prostate cancer cell growth (2). The mechanisms involved were associated with short PRL signaling; however, it was suggested that the short PRL receptor (PRLR) did not induce mammary cell differentiation in response to U-PRL. It has been suggested that the short PRLR lacks the structural Stat5 activation site. Nevertheless, a short mouse PRLR was able to activate mitogen-activated protein kinases (MAPKs), which led to the proliferation of NIH/3T3 cells (3). Binart et al revealed that a short form of mouse PRLR rescues mammopoiesis in heterozygous PRLR mice (4). Notably, we demonstrated that S179D PRL induced β-casein gene expression by regulating the ratio of short to long PRLR in mouse mammary HC11 cells (5). Similarly, Meng et al and Qazi et al identified that a lower ratio of short to long PRLR contributed to breast cancer development, as the short PRLR form inhibited signaling of the long PRLR form via heterodimerization (6,7).

Both the long and the short PRLR forms have been identified in human prostate tissues (8). We previously demonstrated that S179D PRL inhibited prostate cancer DU145 cell growth via the short human PRLR, Sib (2), and inhibited the growth of DU145-derived tumor cells in nude mice (9).

In previous studies, we also revealed that S179D PRL activated short PRLR and ERK1/2 resulting in p21/waf1 expression in prostate cancer cells (2,9). It is well known that p21/waf1 induces cell cycle arrest, differentiation and apoptosis in a number of cell lines. These results indicate that S179D PRL may induce apoptosis via the short PRLR Sib and the upregulation of p21/waf1. Short PRLR signaling may trigger the activation of JNK, c-jun and c-fos, resulting in the activation of activating protein-1 (AP-1) and the upregulation of p21/waf1 in human prostate cancer cells. Previous studies have demonstrated that the accumulation of ERK1/2 resulted in the upregulation of p21 (10-12). Structurally, the short PRLR has the potential to activate Jak 2 and further activate MAPKs. Studies have revealed that the short PRLR activates AP-1 family members, including c-jun and c-fos complexes, and U-PRL induces an increase in the c-jun content of the AP-1 transcriptional complex via activating JNK (13,14). AP-1 was considered to be a regulator of cell death, and p21/waf1 expression correlates with the expression of AP-1 family members.
(c-jun and c-fos) in breast cancer cells (15). Additionally, it has been demonstrated that JNK activation, as well as c-jun and c-fos upregulation, contribute to p21/waf1 expression in selenite-induced HepG2 cell apoptosis. In the present study, we investigated whether S179D PRL activates JNK, c-jun and c-fos, leading to p21/waf1 upregulation and apoptosis in response to S179D PRL in the PC3 cells transfected with human short PRLR S1b. The JNK blocker, SP600125, was used to determine whether JNK signaling contributes to p21/waf1 upregulation. The aim of this study was to uncover the molecular mechanisms associated with S179D PRL and prostate cancer cells.

Materials and methods

Recombinant PRL. DNA cloning and mutagenesis techniques were used to produce U-PRL and S179D PRL, as previously described (5). S179D PRL was generated by substituting an aspartate for a normally phosphorylated serine. The proteins were expressed and purified, and their activity was studied in an Nb2 cell bioassay. U-PRL promotes Nb2 cell proliferation, while S179D PRL antagonizes this effect.

Cell lines and constructs. The PC3 cell line was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). Cells were maintained in RPMI-1640 medium containing 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA) and antibiotics. The constructs pEF4C-S1b and pEF6-LPRLR containing prolactin receptors were gifts from Dr Barbara K. Vonderhaar (National Institute of Health, National Cancer Institute, Bethesda, MD, USA) and the β-galactosidase (β-gal) plasmid was provided by Dr Linda A. Schuler (University of Wisconsin, Madison, WI, USA). AP-1 (7x) was purchased from Stratagene Corp. (La Jolla, CA, USA). The constructs pRSV-jun and pRSV-fos were gifts from Dr Robert Tjian (University of California, Berkeley, CA, USA). The construct p21 Luc was obtained from Dr Leonard P. Freedman (Memorial Sloan-Kettering Cancer Center, New York, NY, USA).

Cotransfection and luciferase assay. PC3 cells were grown in RPMI-1640 medium (Invitrogen) containing 10% charcoal-stripped horse serum (Cocalico Biologicals, Reamstown, PA, USA), 100 U/ml penicillin and 100 µg/ml streptomycin (Invitrogen). Cells were grown in six-well plates and transfection was conducted once the cells reached 50-70% confluency. After transfection efficiency. After cells were treated with PRL (U-PRL and S179D PRL; 1 µg/ml) for three days, the JNK blocker, SP600125 (25 µM; Calbiochem, San Diego, CA, USA), was used to inhibit AP-1 Luc and p21 Luc expression in response to each PRL. In another transfection study involving c-fos and c-jun transfection, c-fos (0.5 µg/5 ml) only, c-jun (0.5 µg/5 ml) only and c-fos (0.25 µg/5 ml) plus c-jun (0.25 µg/5 ml), AP-1 Luc (0.25 µg/5 ml) or p21 luciferase construct (0.25 µg/5 ml), short PRLR (0.25 µg/5 ml) and β-gal plasmids were used to transfect the cells. In the RPMI-1640 medium containing 5% charcoal-stripped horse serum, cells were treated with U-PRL or S179D PRL for 24 h. A volume of 10 µl was applied to test luciferase activity using a luminometer, following the Promega Luciferase assay manufacturer's instructions.

Preparation of whole cell and nuclear extracts. Cells were rinsed with phosphate-buffered saline (PBS) and scraped off in a buffer containing 20 mM Tris-HCl (pH 7.4), 140 mM NaCl, 0.05 mM EDTA, 10 µg/ml leupeptin, 10 µg/ml aprotonin, 25 µg/ml pepstatin, 1 mM PMSF, 1 mM Na2VO4, 10 mM NaF, 1 mM EGTA and 1% NP-40. The cell lysate was homogenized and centrifuged at 12,000 x g for 5 min, and the supernatant was considered as a whole cell extract. The whole cell lysate was used to examine the phosphorylated c-jun (p-c-jun), c-fos (p-c-fos) and JNK (p-JNK). If the cells were scraped into a hypotonic buffer, consisting of 10 mM Tris (pH 7.4), 10 mM NaCl, 6 mM MgCl2, 1 mM dithiothreitol and 0.1 mM Na2VO4, and disrupted with a Dounce homogenizer, the supernatant was removed following centrifugation at 12,000 x g for 5 min. The pellet from the centrifugation was resuspended in hypertonc extraction buffer, consisting of 20% glycerol, 20 mM HEPES (pH 7.4), 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol and 0.1 mM Na2VO4, and incubated on ice for 30 min. The supernatant obtained following centrifugation was a nuclear extract. This was used to examine the p21/waf1 protein concentration, which was calculated using the Bradford method.

Western blot analysis. A total of 20 µg of protein was loaded onto a reducing SDS-PAGE gel. Following electrophoresis, the protein was transferred to nitrocellulose membranes in 48 mM Tris, 39 mM glycine, 0.1% SDS and 20% methanol (pH 8.3). Membranes were blocked with 5% non-fat milk in washing buffer consisting of Dulbecco's PBS (DPBS; Invitrogen) and 0.1% Tween-20. Blotted and blocked membranes were probed with primary rabbit polyclonal anti-p21/waf1 (1:500), anti-c-fos (1:1000), anti-p-c-jun (1:1000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and anti-JNK (1:500; Promega, Madison, WI, USA) in washing buffer for 3 h at room temperature or overnight at 4°C. After washing three times for 15 min each, the blots were incubated in goat anti-rabbit conjugated to horseradish peroxidase (Sigma, St. Louis, MO, USA) at a dilution of 1:2000-1:10000, as appropriate, for 30-45 min at room temperature. Following a further three washes, the membranes were treated with ECL reagent (Amersham Biosciences, Piscataway, NJ, USA) and an autoradiograph image was obtained.

Apoptosis assay. The treated PC3 cells were collected to examine the DNA degradation. DNA was isolated using phenol/chloroform extraction followed by ethanol precipitation procedures. A total of 10 µg of DNA was run on a 0.8% agarose gel. Apoptosis was determined by DNA fragmentation.

Statistical analysis. Data were subjected to analysis of variance with post-tests for comparison among specific groups using the INSTAT program (Graph PAD Software, San Diego, CA, USA). Post-tests comparing each potential pair of groups were conducted. Bonferroni corrections for multiple compari-
sons against a single group were used. All experiments were conducted a minimum of three times. Following Bonferroni corrections, $P<0.05$ was considered to indicate a statistically significant difference.

**Results**

**S179D PRL phosphorylates c-fos, c-jun and JNK.** PC3 cells were treated with U-PRL or S179D PRL for 4 days. Western blot analysis demonstrated that U-PRL and S179D PRL phosphorylated c-fos, c-jun and JNK (Fig. 1A). Apoptosis assays revealed that S179D PRL induced apoptosis in PC3 cells (Fig. 1B); however, U-PRL did not. Previously, we identified that S179D PRL upregulated the short PRLR S1b and ERK1/2 leading to p21 upregulation in PC3 cells (2). These results indicated that the short PRLR S1b and c-jun/c-fos complex (AP-1) may contribute to S179D PRL signaling and apoptosis.

**S179D PRL phosphorylates c-fos, c-jun and JNK in the short PRLR S1b transfected cells.** It was suggested that S1b activated the MAPK pathway; however, in previous studies, S179D PRL did not upregulate S1b following a 24 h incubation (2). In this study, we transfected PC3 cells with S1b, and either c-fos, c-jun or c-fos/c-jun constructs, in order to observe the activation of c-fos, c-jun or c-jun/c-fos. Following transfection, cells were treated with U-PRL or S179D PRL. The results demonstrated that U-PRL and S179D PRL activated c-fos, c-jun and JNK in c-fos, c-jun and c-fos/c-jun transfected cells to a certain extent (Fig. 2A). These data reveal that S1b is involved in the activation of c-fos, c-jun and JNK in S179D PRL treated PC3 cells. Additionally, apoptosis was only observed in c-fos/c-jun-transfected cells, but not in the c-fos- or c-jun-only-transfected cells (Fig. 2B), which suggests that AP-1 contributes to apoptosis.

**S179D PRL increases p21 luciferase activity.** Activated MAPK (ERK1/2 and JNK) was demonstrated to activate AP-1 complexes (c-jun/c-jun or c-jun/c-fos dimers) in a number of cell types (13-15). In this study, cells were transfected with S1b, either c-fos, c-jun or c-fos/c-jun and p21 Luc constructs, after 24-h incubation with S179D PRL. The results revealed that S179D PRL increased p21 luciferase activity in c-fos/c-jun transfected cells only (Fig. 3B).

**SP600125 inhibits AP-1 or p21 luciferase activity.** In this study, we examined the AP-1 (7x) and p21 luciferase activity after PC3 cells were transfected with S1b c-fos/c-jun constructs in response to S179D PRL and the JNK blocker, SP600125 (25 µM). After 24-h incubation, the results demonstrated that SP600125 inhibited AP-1 and p21 luciferase activity induced by S179D PRL (Fig. 4A and B). Since the activation of c-fos depends on activated ERK1/2 (15), both

---

Figure 1. PC3 cells were incubated with U-PRL or S179D PRL for four days. (A) Western blot analysis demonstrated that U-PRL and S179D PRL phosphorylated c-fos, c-jun and JNK. Experiments were conducted in triplicate. β-actin was used for normalization and equal loading. (B) Genomic DNA was isolated and loaded onto a 0.8% agarose gel. Smeared-laddered bands indicate the apoptotic effect. S179D PRL triggers apoptosis in PC3 cells; however, U-PRL does not. Experiments were conducted in duplicate. CON, control; U, unmodified; p, phosphorylated; JNK, c-jun N-terminal kinase. PRL, prolactin.

Figure 2. (A) Western blot analysis revealed that U-PRL phosphorylates c-fos, c-jun and JNK after a 24 h incubation in the c-jun- and c-fos/c-jun-transfected cells but not the c-fos-transfected cells. S179D PRL phosphorylates c-fos, c-jun and JNK after a 24 h incubation in the c-fos, c-jun and c-fos/c-jun short PRLR S1b-transfected cells. (B) Apoptosis was only observed in the cells transfected with c-fos/c-jun and S1b in response to S179D PRL. All experiments were conducted in duplicate. con, control; U-PRL, unmodified prolactin; p, phosphorylated; JNK, c-jun N-terminal kinase.
activated ERK1/2 and JNK contributed to the activation of AP-1 and p21 upregulation.

Discussion

In the previous studies, we demonstrated that S179D PRL inhibited prostate cancer in vitro and in vivo (1,9). In the present study, we identified that S179D PRL induced apoptosis via activating AP-1 and upregulating p21/waf1 in PC3 cells. Increased p21 and apoptosis requires short human PRLR S1b and c-fos/c-jun heterodimerization. We previously demonstrated that S179D PRL primarily used the ERK1/2 pathways to activate downstream genes, including Stat5 and p21/waf1 (5). The short PRLR may play a role in signaling. Structurally, the short PRLR has the potential to activate Jak2, which is able to further activate the ERK1/2 pathway. In certain cell types, sustained ERK1/2 activation also leads to p21/waf1 upregulation, cell cycle arrest, differentiation and apoptosis (10-12). In the p21 gene promoter region, there are 2 Stat5 activating sites; however, it is unclear whether S179D PRL upregulates p21/waf1 via Stat5 activation. Serine phosphorylation of Stat5 was revealed to have a more stable binding affinity to the gene promoter (5); therefore, the short PRLR S1b may contribute to Stat5 activation leading to p21/waf1 upregulation and apoptosis. Thus, the short PRLR has the potential to trigger various signaling pathways. Additionally, S179D PRL may induce mRNA alternative splicing to maintain a stable ratio of long and short PRLR (6,7). Studies have demonstrated that activated AP-1 causes a p21/waf1 increase (16).

In the present study, we first identified that S179D PRL upregulated p21, which resulted from c-fos/c-jun heterodimerization. In the c-fos or c-jun only-transfected PC3 cells, p21/waf1 was not upregulated, suggesting that S179D PRL only induced c-fos/c-jun heterodimerization and not c-fos or c-jun homodimerization. The JNK blocker, SP600125, inhibited S179D PRL-induced AP-1 activation and p21/waf1 upregulation by blocking the c-fos/c-jun dimerization. We found that S179D PRL also phosphorylated JNK. Whether the short PRLR is necessary for this activation requires further investigation; however, p21/waf1 upregulation requires the short PRLR S1b. In a previous study, we revealed that the p21/waf1 increase was induced by upregulating the short PRLR S1b and activating ERK1/2. S179D PRL may activate p21/waf1 via activating ERK1/2 and JNK. It is unknown whether MAPK translocates into the nucleus; however, activated c-fos/c-jun (AP-1) was found to induce apoptosis in numerous cell lines, and a particular conformation of the c-fos/c-jun complex is necessary for AP-1 to bind to p21/waf1. Consequently, S179D PRL may inhibit prostate cancer via apoptosis. In these studies, U-PRL also phosphorylated JNK and c-jun; however, no apoptotic effect was identified. JNK is a c-jun N-terminal kinase; therefore, activated JNK may not activate c-fos since c-fos was activated by ERK1/2. U-PRL triggers the Jak2-Stat5 pathway via activating the long PRLR rather than the short PRLR. This effect has been revealed to contribute to cancer cell proliferation (13,17). The short PRLR resulted from the translation of alternatively spliced mRNA. These PRLRs may constitute a regulatory system to regulate the long PRLR signaling. Additionally, S179D PRL,
a U-PRLR antagonist, may also block the U-PRL signals by competing with the long PRLR. Nevertheless, S179D PRL primarily uses the short PRLR to activate ERK1/2, JNK and transcription factors, leading to p21/waf1 upregulation and apoptosis.

In conclusion, S179S PRL activated c-fos, c-jun and JNK leading to p21/waf1 upregulation and apoptosis, suggesting that S179D PRL may be used as a potential drug to repress prostate cancer.

Acknowledgements

We are grateful to Dr Ameae Walker, (University of California, Riverside, CA, USA) for her support in the experiments. This study was supported by The Science and Development Plan of Beijing Education Committee (Grant No. KM200910025008) and The National Natural Science Foundation of China (Grant No. 81041067). We would also like to thank Dr Barbara K. Vonderhaar (NCI NIH, Bethesda, MD, USA), Dr Linda A. Schuler (University of Wisconsin, Madison, WI, USA), Dr Leopard Freeman (Memorial Sloan-Kettering Cancer Center, New York, NY, USA), and Dr Robert Tijan (University of California, Berkeley, CA, USA) for their generosity in providing constructs.

References


